Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for targeted treatments and achieving long-term remission.

A prospective registry study found a greater risk for infections associated with JAK inhibitors in adolescents and adults with moderate to severe atopic dermatitis compared with biologics.

SinoMab BioScience Limited (Stock Code: 3681.HK, “SinoMab” or the “Company”), is pleased to announce our breakthrough topline results from the completed Phase 1b clinical study evaluating SM17, a ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Some topical cannabinoid therapies could be a safe and effective treatment for patients with atopic dermatitis (AD) says a ...

In this video, Peter Lio, MD, discussed updates on topical agents, biologics and drugs in the pipeline in atopic dermatitis from presentations at the American Academy of Dermatology meeting.

In this video, Raj Chovatiya, MD, PhD, discussed continued updates in the use of topical ruxolitinib in pediatric patients with atopic dermatitis.